Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance.

Reinhardt F, Franken A, Meier-Stiegen F, Driemel C, Stoecklein NH, Fischer JC, Niederacher D, Ruckhaeberle E, Fehm T, Neubauer H.

Cancers (Basel). 2019 Jun 28;11(7). pii: E903. doi: 10.3390/cancers11070903.

2.

Long-term cosmetic outcome after preoperative radio-/chemotherapy in locally advanced breast cancer patients.

Matuschek C, Nestle-Kraemling C, Haussmann J, Bölke E, Wollandt S, Speer V, Djiepmo Njanang FJ, Tamaskovics B, Gerber PA, Orth K, Ruckhaeberle E, Fehm T, Corradini S, Lammering G, Mohrmann S, Audretsch W, Roth S, Kammers K, Budach W.

Strahlenther Onkol. 2019 Jul;195(7):615-628. doi: 10.1007/s00066-019-01473-2. Epub 2019 May 17.

PMID:
31101954
3.

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A, Niederacher D, Fischer JC, Stoecklein NH, Ruckhaeberle E, Fehm T, Neubauer H.

Clin Chem. 2019 Apr;65(4):549-558. doi: 10.1373/clinchem.2018.296814. Epub 2019 Feb 8.

PMID:
30737205
4.

Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.

Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E, Fehm T.

Biomed Res Int. 2014;2014:415721. doi: 10.1155/2014/415721. Epub 2014 May 8. Review.

5.

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.

Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T.

Breast Cancer Res Treat. 2013 Jan;137(2):407-16. doi: 10.1007/s10549-012-2356-2. Epub 2012 Dec 16.

PMID:
23242614
6.

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L.

Ann Surg Oncol. 2012 May;19(5):1508-16. doi: 10.1245/s10434-011-2108-2. Epub 2011 Dec 23.

PMID:
22193884
7.

A clinically relevant gene signature in triple negative and basal-like breast cancer.

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M.

Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.

8.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. Epub 2009 Mar 9.

Supplemental Content

Loading ...
Support Center